Health Care
Proteomics International Laboratories Ltd (PIQ)
Proteomics International Laboratories Ltd (ASX: PIQ) is a medical technology company focused on proteomics, the large-scale study of proteins. Its lead product, PromarkerD, is a predictive diagnostic test for diabetic kidney disease, which it is commercialising globally. The company operates from its headquarters in Perth, Western Australia, and is also developing a pipeline of other diagnostic tests for diseases like endometriosis and oesophageal cancer.
Market Cap
A$81M
Shares on Issue
N/A
Price Chart
AI Analysis
With a market capitalisation of approximately A$81M, PIQ is a speculative small-cap biotechnology company heavily focused on the global commercialisation of its PromarkerD test. The company's recent performance has been driven by progress in securing regulatory approvals and reimbursement pathways, particularly in the key US market. Financially, PIQ is in a pre-profitability stage, generating initial revenues from early sales but still incurring significant expenses for research, development, and market access activities, making its quarterly cash flow (Appendix 4C) a critical metric for investors to monitor.
PIQ's growth outlook is almost entirely dependent on achieving widespread clinical adoption and reimbursement for PromarkerD. The primary catalyst is obtaining a unique CPT reimbursement code in the United States, which would unlock access to the world's largest healthcare market and significantly accelerate revenue growth. The company's strategic direction also involves expanding its diagnostic pipeline using its proprietary proteomics platform, which offers long-term, blue-sky potential but currently contributes no revenue and requires further R&D investment.
Bull Case
- • Huge addressable market for PromarkerD, with millions of diabetics globally at risk of kidney disease, offering transformative revenue potential.
- • Regulatory momentum, particularly progress with the US FDA De Novo application, de-risks the technology and opens up major commercial markets.
- • Proprietary technology platform (Promarker) offers a pipeline of future diagnostic tests for other major diseases, providing long-term growth optionality beyond the initial product.
Bear Case
- • Significant commercialisation risk; securing widespread adoption and reimbursement from complex healthcare systems is a slow, costly, and uncertain process.
- • Ongoing cash burn requires future capital raises, which could lead to significant dilution for existing shareholders.
- • Heavy reliance on a single product (PromarkerD) in the short-to-medium term, making the company highly vulnerable to competition or setbacks with that specific test.
Recent Announcements
Resignation of Joint Company Secretary
Application for quotation of securities - PIQ
Quarterly Activities/Appendix 4C Cash Flow Report
🚨 Price SensitiveThe ASX announcement for company ticker PIQ reveals a detailed quarterly cash flow report, indicating their financial health and liquidity position. Investors should review the appendix to assess potential investment opportunities based on this critical financial metric.
Application for quotation of securities - PIQ
Initial Director's Interest Notice
FAQs
What does PIQ do?
PIQ is a medical technology company that uses the study of proteins (proteomics) to develop diagnostic tests. Its flagship product is PromarkerD, a simple blood test designed to predict the onset of diabetic kidney disease before clinical symptoms appear.
Is PIQ a good investment?
PIQ is a high-risk, high-reward investment. The potential success of its PromarkerD test in the massive global diabetes market offers significant upside. However, as a pre-profitability biotech, it faces major risks related to regulatory approval, securing reimbursement, competition, and the need for future funding.
What drives PIQ's share price?
The share price is primarily driven by news flow and key catalysts. These include regulatory decisions (especially from the US FDA), securing commercial agreements with diagnostic labs or healthcare providers, clinical trial results, and the company's cash position and any potential capital raisings.
Key Metrics
Related Stocks
Health Care
CSLCSL Ltd
A$181.24
-27.3% 1Y
CSL is a global biotechnology leader focused on plasma-derived therapies, vaccines, and specialty biologics.
Health Care
PNVPolynovo Ltd
A$0.99
-13.1% 1Y
Polynovo manufactures innovative wound care products used in burns, trauma, and reconstructive surgery.
Health Care
1ADAdalta Limited
A$0.01
-25.6% 1Y
Adalta Limited is a clinical-stage biotechnology company developing its proprietary i-body technology platform for treating a range of diseases. Based in Australia, its lead product candidate, AD-214, is being developed to treat Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases.